Astria Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021	Q1 FY2021 As of Mar 31, 2021	Q3 FY2020 As of Sep 30, 2020
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable
Prepaid expenses and other current assets
Total current assets
Right-of-use asset
Other assets
Total assets
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
Accrued expenses
Operating lease liabilities, current
Deferred revenue, current
Total current liabilities
Warrant liability
Operating lease liabilities, net of current portion
Deferred revenue, net of current portion
Total liabilities
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 86,077 shares issued and outstanding as of March 31, 2021 and no shares issued and outstanding as of December 31, 2020
Stockholders' equity:
Preferred stock
Series X redeemable convertible preferred stock
Series X Redeemable Convertible Preferred Stock
Total series X redeemable convertible preferred stock

Total preferred stock

Common stock, $0.001 par value per share, 150,000,000 shares authorized; 56,434,894 and 56,434,219 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively
Additional paid-in capital
Accumulated other comprehensive gain
Accumulated deficit
Total stockholders' equity
Total liabilities and stockholders' equity

Comments